US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 4975369A
· Beavers et al.
· 1990
[cited by applicant]
US 5001065A
· Larrick et al.
· 1991
[cited by applicant]
US 5075431A
· Shively et al.
· 1991
[cited by applicant]
US 5081235A
· Shively et al.
· 1992
[cited by applicant]
US 5169939A
· Gefter et al.
· 1992
[cited by applicant]
US 5202238A
· Fell, Jr. et al.
· 1993
[cited by applicant]
US 5204244A
· Fell et al.
· 1993
[cited by applicant]
US 5231026A
· Chang
· 1993
[cited by applicant]
US 5292867A
· Chang
· 1994
[cited by applicant]
US 5354847A
· Liu et al.
· 1994
[cited by applicant]
US 5472693A
· Gourlie et al.
· 1995
[cited by applicant]
US 5482856A
· Fell, Jr. et al.
· 1996
[cited by applicant]
US 5491088A
· Hellstrom et al.
· 1996
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5502167A
· Waldmann et al.
· 1996
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5622425A
· Lin
· 1997
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Nils et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 6927286B1
· Shen
· 2005
[cited by examiner]
US 7695936B2
· Carter et al.
· 2010
[cited by applicant]
US 9862778B2
· Glen et al.
· 2018
[cited by applicant]
US 20130259878A1
· Terrett
· 2013
[cited by applicant]
US 20140363454A1
· Jackson
· 2014
[cited by examiner]
US 20150093392A1
· Terrett et al.
· 2015
[cited by applicant]
US 20150352230A1
· Mullen
· 2015
[cited by examiner]
US 20160311921A1
· Schweizer et al.
· 2016
[cited by applicant]
US 20180147294A1
· Jackson
· 2018
[cited by examiner]
US 20190209704A1
· Jackson
· 2019
[cited by examiner]
US 20230270881A1
· Bhatnagar et al.
· 2023
[cited by applicant]
EP 3710482A4
· 2020
[cited by applicant]
WO WO2011039126A1
· 2011
[cited by applicant]
WO WO2012061759A2
· 2012
[cited by applicant]
WO WO2013055958A1
· 2013
[cited by applicant]
WO WO2014161845A1
· 2014
[cited by applicant]
WO 2014191578
· 2014
[cited by examiner]
WO WO2016079050
· 2016
[cited by examiner]
WO WO2017093447A1
· 2017
[cited by applicant]
WO 2018052556
· 2018
[cited by examiner]
WO 2023023677
· 2023
[cited by examiner]
Shivange et al (Cancer Cell. Aug. 13, 2018; 34(2): 331-345).
[cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021).
[cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020).
[cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021 ).
[cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021).
[cited by examiner]
Tushir-Singh (FASEB Journal, (Apr. 2019) vol. 33, No. Suppl. 1, pp. 647.44. Meeting Info.: Experimental Biology Meeting (EB). Orlando, FL, USA. Apr. 6 -9, 2019. Amer Assoc Anat; Amer Physiol Soc; Amer Soc Biochem & Mol …
[cited by examiner]
Tushir-Singh (FASEB Journal, (Apr. 2019) vol. 33, No. SUPPL 1, pp. 647.44. Meeting Info: Experimental Biology, EB 2019. Orlando, FL, United States. Apr. 6, 2019-Apr. 9, 2019).
[cited by examiner]
Armstrong et al., “Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.” Gynecol Oncol, vol. 129, pp. 452-458 (2013).
[cited by applicant]
Ashkenazi et al., “To kill a tumor cell: the potential of proapoptotic receptor agonists.” J Clin Invest, vol. 118, pp. 1979-1990 (2008).
[cited by applicant]
Ashkenazi, “Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.” Nat Rev Drug Discov, vol. 7, pp. 1001-1012 (2008).
[cited by applicant]
Ashkenazi, “Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions.” J Clin Invest, vol. 125, pp. 487-489 (2015).
[cited by applicant]
Barbas et al., “Synthetic human antibodies.” Nature Medicine, vol. 1, pp. 837-839 (1995).
[cited by applicant]
Bauer et al., “Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.” Arthritis Res Ther vol. 8, Article ID R171 (2006).
[cited by applicant]
Berek et al., “Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.” J Clin Oncol, vol. 27, pp. 418-425 (2009).
[cited by applicant]
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes.” J Immunol, vol. 147, pp. 86-95 (1991).
[cited by applicant]
Brinkmann et al., “The making of bispecific antibodies.” MAbs, vol. 9, pp. 182-212 (2017).
[cited by applicant]
Brunker et al., “RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP- Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.” Mol Cancer Ther, vol. 15, pp. 946-957 (2016).
[cited by applicant]
Chen et al., “Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma.” World J Gastroenterol, vol. 18, pp. 7251-7261 (2012).
[cited by applicant]
Chou et al., “Prediction of beta-turns.” Biophys J, vol. 26, pp. 367-384 (1979).
[cited by applicant]
Cole et al., “Human monoclonal antibodies.” Mol Cell Biol, vol. 62, pp. 109-120 (1984).
[cited by applicant]
Conrad et al., “In vitro selection methodologies to probe RNA function and structure.” Mol Div, vol. 1, pp. 69-78 (1995).
[cited by applicant]
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens.” Proc Natl Acad Sci USA, vol. 80, pp. 2026-2030 (1983).
[cited by applicant]
Day et al., “Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?” PLoS Comput Biol, vol. 12, Article ID e1004689 (2016).
[cited by applicant]
De Kruif et al., “Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions.” J Mol Biol, vol. 248, pp. 97-105 (1995).
[cited by applicant]
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX.” Nucleic Acids Res, vol. 12, pp. 387-395 (1984).
[cited by applicant]
Domcke et al., “Evaluating cell lines as tumour models by comparison of genomic profiles.” Nat Commun, vol. 4, Article ID 2126 (2013).
[cited by applicant]
Durocher et al., “Expression systems for therapeutic glycoprotein production.” Curr Opin Biotechnol, vol. 20, pp. 700-707 (2009).
[cited by applicant]
Ellington, “RNA Selection: Aptamers achieve the desired recognition.” Curr Biol, vol. 4, pp. 427-429 (1994).
[cited by applicant]
European Search Report corresponding to European Patent Application No. 18879754.2 dated Jul. 15, 2021.
[cited by applicant]
Fishwild et al., “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice.” Nature Biotechnology, vol. 14, pp. 845-851 (1996).
[cited by applicant]
Glund et al., “Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.” J Am Coll Cardiol, vol. 67, pp. 1654-1656 (2016).
[cited by applicant]
Godwin et al., “Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.” Front Oncol, vol. 3, p. 120 (2013).
[cited by applicant]
Graves et al., “Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.” Cancer Cell, vol. 26, pp. 177-189 (2014).
[cited by applicant]
Gu et al., “Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.” Methods Enzymol, vol. 502, pp. 25-41 (2012).
[cited by applicant]
Hoogenboom et al., “By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro.” J Mol Biol, vol. 227, pp. 381-388 (1992).
[cited by applicant]
Houston, Methods in Enzymol, vol. 203, pp. 46-88 (1991).
[cited by applicant]
Huse et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda.” Science, vol. 246, pp. 1275-1281 (1989).
[cited by applicant]
Hutt et al., “Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.” J Biol Chem, vol. 287, pp. 4462-4469 (2012).
[cited by applicant]
International Preliminary Report on Patentability Corresponding to International application No. PCT/US 2018/060735 dated May 19, 2020.
[cited by applicant]
International Search Report Corresponding to International application No. PCT/US 2018/060735 dated Apr. 19, 2019.
[cited by applicant]
Jakob et al., “Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule.” MAbs, vol. 5, pp. 358-363 (2013).
[cited by applicant]
Jin et al., “Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.” J Biol…
[cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse.” Nature, vol. 321, pp. 522-525 (1986).
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences.” Proc Natl Acad Sci USA, vol. 90, pp. 5873-5877 (1993).
[cited by applicant]
Karlin et al., “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.” Proc Natl Acad Sci USA, vol. 87, pp. 2264-2268 (1990).
[cited by applicant]
Kline et al., “Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-gamma receptor engagement.” Oncotarget, vol. 8, pp. 52045-52060 (2017).
[cited by applicant]
Klug et al., “All you wanted to know about SELEX.” Mol Biol Reports, vol. 20, pp. 97-107 (1994).
[cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature, vol. 256, pp. 495-497 (1975).
[cited by applicant]
Kozbor et al., “Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas.” J Immunol Methods, vol. 81, pp. 31-42 (1985).
[cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes.” Immunology Today, vol. 4, pp. 72-78 (1983).
[cited by applicant]
Kyte et al., “A simple method for displaying the hydropathic character of a protein.” J Mol Biol, vol. 157, pp. 105-132 (1982).
[cited by applicant]
Lato et al., “In vitro selection of RNA lectins: using combinatorial chemistry to interpret ribozyme evolution.” Chem Biol, vol. 2, pp. 291-303 (1995).
[cited by applicant]
Leabman et al., “Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys.” MAbs, vol. 5, pp. 896-903 (2013).
[cited by applicant]
LeBlanc et al., “Tumor-cell resistance to death receptor—induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.” Nat Med, vol. 8, pp. 274-281 (2002).
[cited by applicant]
Levett et al., “Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus.” J Clin Microbiol, vol. 43, pp. 5873-5875 (2005).
[cited by applicant]
Li et al., “Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement.” Proc Natl Acad Sci USA, vol. 109, pp. 10966-10971 (2012).
[cited by applicant]
Lin et al., “The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.” Cancer Biol Ther, vol. 14, pp…
[cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications.” Nature, vol. 368, pp. 856-859 (1994).
[cited by applicant]
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling.” Bio/Technology, vol. 10, pp. 779-783 (1992).
[cited by applicant]
Marks et al., “By-passing immunization: Human antibodies from V-gene libraries displayed on phage.” J Mol Biol, vol. 222, pp. 581-597 (1991).
[cited by applicant]
Merchant et al., “Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.” J Clin Oncol, vol. 30, pp. 4141-4147 (2012).
[cited by applicant]
Mongkolsapaya et al., “Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.” Nat Struct Biol, vol. 6, pp. 1048-1053 (1999).
[cited by applicant]
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains.” Proc Natl Acad Sci USA, vol. 81, pp. 6851-6855 (1984).
[cited by applicant]
Morrison, “Success in specification.” Nature, vol. 368, pp. 812-813 (1994).
[cited by applicant]
Neuberger et al., “Recombinant antibodies possessing novel effector functions.” Nature, vol. 312, pp. 604-608 (1984).
[cited by applicant]
Neuberger, “Generating high-avidity human Mabs in mice.” Nature Biotechnology, vol. 14, p. 826 (1996).
[cited by applicant]
Niyazi et al., “Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.” Oncol Rep, vol. 21, pp. 1455-1460 (2009).
[cited by applicant]
Notice of Publication corresponding to European Patent Application No. 18879754.2 dated Aug. 26, 2020.
[cited by applicant]
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.” Proc Natl Acad Sci USA, vol. 86, pp. 3833-3837 (1989).
[cited by applicant]
Ouellet et al., “An Apoptotic Molecular Network Identified by Microarray: On the TRAIL to New Insights in Epithelial Ovarian Cancer.” Cancer, vol. 110(2), pp. 297-308 (2007).
[cited by applicant]
Paz-Ares et al., “A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.” J Thorac Oncol, vol. 8, pp. 329-337 (2013).
[cited by applicant]
Presta, “Antibody engineering.” Curr Op Struct Biol, vol. 2, pp. 593-596 (1992).
[cited by applicant]
Printz, “Cancer drug safety presents challenges: oncologists, researchers, and government balance risks with benefits.” Cancer, vol. 117, pp. 5023-5025 (2011).
[cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.” Protein Eng, vol. 9, pp. 617-621 (1996).
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy.” Nature, vol. 332, pp. 323-329 (1988).
[cited by applicant]
Sasaki et al., “A phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors.” Invest New Drugs, vol. 33, pp. 332-340 (2015).
[cited by applicant]
Saunders et al., “Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.” EMBO Mol Med, vol. 4, pp. 675-684 (2012).
[cited by applicant]
Schaefer et al., “A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.” Cancer Cell, vol. 20, pp. 472-486 (2011).
[cited by applicant]
Soria et al., “Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.” J Clin Oncol v…
[cited by applicant]
Spiess et al., “Alternative molecular formats and therapeutic applications for bispecific antibodies.” Mol Immunol, vol. 67, pp. 95-106 (2015).
[cited by applicant]
Takeda et al., “Construction of Chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences.” Nature, vol. 314, pp. 452-454 (1985).
[cited by applicant]
Takeda et al., “Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.” Proc Natl Acad Sci USA, vol. 105, pp. 10895-10900 (2008).
[cited by applicant]
Tran et al., “Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.” J Exp Med, vol. 210, pp. 1125-1135 (2013).
[cited by applicant]
Tuszynski et al., “Thrombospondin Promotes Platelet Aggregation.” Blood, vol. 72, pp. 109-115 (1988).
[cited by applicant]
Uphoff et al., “In vitro selection of aptamers: the dearth of pure reason.” Curr Opin Struct Biol, vol. 6, pp. 281-287 (1996).
[cited by applicant]
Vergote et al., “A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First P…
[cited by applicant]
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity.” Science, vol. 239, pp. 1534-1536 (1988).
[cited by applicant]
Vincenzi et al., “Drug-induced hepatotoxicity in cancer patients—implication for treatment.” Expert Opin Drug Saf, vol. 15, pp. 1219-1238 (2016).
[cited by applicant]
Wagner et al., “Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.” Nat Med vol. 13, pp. 1070-1077 (2007).
[cited by applicant]
Wakelee et al., “Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.” Ann Oncol, vol. 21, pp. 376-381 (2010).
[cited by applicant]
Wallis et al., “A novel RNA motif for neomycin recognition.” Chem Biol, vol. 2, pp. 543-552 (1995).
[cited by applicant]
Wang et al., “The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.” Curr Pharm Des, vol. 20, pp. 6714-6722 (2014).
[cited by applicant]
Wilson et al., “An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.” Cancer Cell, vol. 19, pp. 101-113 (2011).
[cited by applicant]
Winter et al., “Man-made antibodies.” Nature, vol. 349, pp. 293-299 (1991).
[cited by applicant]
Written Opinion of the International Searching Authority Corresponding to International application No. PCT/US 2018/060735 dated Apr. 19, 2019.
[cited by applicant]
Zhang et al., “3D Structural Fluctuation of IgG1 Antibody Revealed by Individual Particle Electron Tomography.” Sci Rep, vol. 5, pp. Article No. 9803 (2015).
[cited by applicant]
Zuch de Zafra et al., “Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.” Cell Death Dis, vol. 7, Article ID e2338 (2016).
[cited by applicant]
Digiammarino, E., et al., “Design and generation of DVD-Ig molecules for dual-specific targeting”, in Methods Mol Biol, vol. 899, 2012, pp. 145-156.
[cited by applicant]
Ecker, D. M., et al., (2015). “The therapeutic monoclonal antibody market”, in Mabs, vol. 7,2015, pp. 9-14.
[cited by applicant]
Frolova, O., et al. “Regulation of HIF-lalpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment”, in Cancer Biol Ther, vol. 13, 2012, pp. 858-870.
[cited by applicant]
Garber, K., “Bispecific antibodies rise again” in Nat Rev Drug Discov, 2014, pp. 799-801.
[cited by applicant]
Herbst, R. S., et al., “A first-in-human study 30 of conatumumab in adult patients with advanced solid tumors”, in Clin Cancer Res, vol. 16, 2010 b, pp. 5883-5891.
[cited by applicant]
Herbst, R. S., et al., “Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer”, in J Clin Oncol 28, 2010a, pp. 2839-2846.
[cited by applicant]
Kang, J., et al., “Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines”, in Br J Haematol, vol. 123, pp. 921-932.
[cited by applicant]
Kindler, H. L., et al. , “A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer”, in Ann Oncol, vol.…
[cited by applicant]
Kohrt, H. E., et al., “Combination strategies to enhance antitumor ADCC”, Immunotherapy, vol. 4, 2012, pp. 511-527.
[cited by applicant]
Kontermann, R. E. “Dual targeting strategies with bispecific antibodies”, in MAbs , vol. 4, 2012, pp. 182-197.
[cited by applicant]
Lacy, S. E., et al., “Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-lalpha and IL-Ibeta”, in Mabs, vol. 7, 201…
[cited by applicant]
Lu, M., et al., “E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis”, in Mol Cell, vol. 54, 2014, pp. 987-998.
[cited by applicant]
Mahalingam, D., et al., “Targeting TRAIL towards the clinic”, in Curr Drug Targets, vol. 12, 2011, pp. 2079-2090.
[cited by applicant]
O'shannessy, D. J., et al., “Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type”, in Int J Gynecol Pathol 32, 2013, pp. 258-268.
[cited by applicant]
Office Action corresponding to European Patent Application No. 18879754.2 dated Feb. 8, 2024.
[cited by applicant]
Plummer, R., et al., “Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers”, in Clin Cancer Res, vol. 13, 2007, pp. 6187-6194.
[cited by applicant]
Sabbatini, P., et al., “Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, Gineco, and GEICO—the MIMOSA study”, J Clin Oncol, 2013, vol. 31, pp. 1554-1…
[cited by applicant]
Sandilands, G. P., et al., (2010). “Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy”, in Clin Exp Immunol, vol. 162, 2010, pp. 516-527.
[cited by applicant]
Shanker, A., et al., “Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody”, In J Natl Cancer Inst , vol. 100, 2008, pp. 649-662.
[cited by applicant]
Shimizu, A., et al., “H NMR studies of the Fc region of human IgG1 and IgG3 immunoglobulins: assignment of histidine resonances in the CH3 domain and identification of IgG3 protein carrying G3m(st) allotypes”, in Mol Im…
[cited by applicant]
Silacci, M., et al., “Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases”, in Mabs, vol. 8, 2016, pp. 141-149.
[cited by applicant]
Stevenson, G. T. “Three major uncertainties in the antibody therapy of cancer”, in Haematologica 99, 2014, pp. 1538-1546.
[cited by applicant]
Swiech, K., et al., “Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII”, in BMC Biotechnol 11, 2011, pp114.
[cited by applicant]
Takeda, K., et al.,“Induction of tumor-specific T cell immunity by anti-DRS antibody therapy”, In J Exp Med 199, 2004, pp. 437-448.
[cited by applicant]
Topalian, S. L., et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer”, in N Engl J Med, vol. 366, 2012, pp. 2443-2454.
[cited by applicant]
Topp, M. S., et al., “Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study”, Lancet Oncol, vol. 16, 2015,…
[cited by applicant]
Uno, T., et al.,“Eradication of established tumors in mice by a combination antibody-based therapy”, In Nat Med, vol. 12, 2006, pp. 693-698.
[cited by applicant]
Walter, R. B. “ Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia”, In Expert Rev Hematol , vol. 7 , 2014, pp. 317-319.
[cited by applicant]
Wickramasinghe, D. “Tumor and T cell engagement by BITE”, in Discov Med 16, 2013, pp. 149-152.
[cited by applicant]
Williams, K. A., et al., “Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival”, in PLoS One 9, 2014, e88334.
[cited by applicant]
Xin, L., et al., “Human monoclonal antibodies in cancer therapy: a review of recent developments”, In Front Biosci (Landmark Ed) vol. 18, 2013, pp. 765-772.
[cited by applicant]
Carter, P., “Bispecific Human IgG by Design,” Journal of Immunological Methods, vol. 248, Issue. (1-2), Feb. 1, 2001, pp. 7-15.
[cited by applicant]
Teleb et al., “Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran.” Cardiovasc Hematol Disord Drug Targets, vol. 16, pp. 25-29 (2016).
[cited by applicant]
Tushir-Singh, “Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.” Expert Opin Biol Ther, vol. 17, pp. 325-338 (2017).
[cited by applicant]